Important note: This is a highly specialized private clinic focused on cancer immunotherapy. Most treatments are outpatient, by appointment only, and coordinated through medical facilitators for international patients.
Official Name:
- EN: HASUMI Immuno Clinic; ICVS Tokyo Clinic & Research Institute; Shukokai Clinic
- JP: 蓮見免疫クリニック / 珠光会診療所
Country, City, Address:
Japan, Tokyo, Chiyoda Ward. The clinic operates across three linked facilities:
| Facility | Address |
|---|---|
| HASUMI Immuno Clinic | New Otani Garden Court 1F, Kioicho, Chiyoda, Tokyo |
| ICVS Tokyo Clinic | Shin Kioi‑cho Building 4F, 4‑1 Kioi‑cho, Chiyoda‑ku, Tokyo 102‑0094 |
| Shukokai Clinic | 1‑44‑6 Asagaya‑kita, Suginami‑ku, Tokyo 166‑0001 |
Kioicho is a prestigious central Tokyo district, close to Akasaka and the Imperial Palace.
Year of Establishment:
- 1948 — Dr. Kiichiro Hasumi (father of Kenichiro Hasumi) developed the original Hasumi Vaccine (HV) and began clinical use to prevent recurrence after surgery.
- 1988 — Dr. Kenichiro Hasumi became Chairman of Shukokai Inc. (Shukokai Clinic).
- 1999 — Hasumi International Research Foundation (HIRF) established in the USA.
- 2008 — ICVS Tokyo Clinic founded as a dedicated center for HITV therapy.
Type of Clinic:
Specialized private oncology‑immunology clinic. Not a general hospital or inpatient facility — outpatient‑focused, appointment‑only. Core focus: cancer immunotherapy using dendritic cells and vaccine technologies.
Main Specializations:
| Specialty | Details |
|---|---|
| HITV Therapy (Human Initiated Therapeutic Vaccine) | Flagship treatment — intratumoral injections of immature dendritic cells (iDC) combined with IMRT (tomotherapy) |
| preHITV Therapy | Prevention of recurrence and metastasis after surgery (stages I–II); claimed efficacy >90% |
| Hasumi Vaccine (HV) | Preventive and recurrence‑prevention vaccine; in use since 1948, administered to over 100,000 patients across 20+ countries |
| NK Cell Therapy | Activation of natural killer cells |
| LAK Therapy | Lymphokine‑activated killer cells |
| Gamma‑Delta T‑Cell Therapy | |
| CTL Therapy | Cytotoxic T‑lymphocyte therapy (option for recurrences after HITV) |
| Adjuvant Therapy | Supportive immunological agents |
Key Technologies:
- HITV (Human Initiated Therapeutic Vaccine) — patented method (US patent, December 13, 2011). Immature dendritic cells (iDC) are injected directly into the tumor under CT guidance; 24 hours later, activated T cells (AT) are administered intravenously. After 3–5 days, IMRT (tomotherapy) is delivered to the same sites, followed by a second injection of iDC and AT.
- HITV + IMRT Combination — multimodal approach: radiation reduces tumor mass and induces apoptosis with antigen release; these antigens are captured by the injected dendritic cells, triggering a systemic immune response.
- Adjuvant LTE — a cocktail of unsaturated fatty acids, phospholipids, and prostaglandins to boost immune response.
- KLH (Keyhole Limpet Hemocyanin) — used as a marker to assess dendritic cell functionality.
- In‑House Cell Processing Center (CPC) — certified lab for culturing dendritic cells and T cells from the patient’s blood.
- Scientific Collaboration with Late Prof. Ralph Steinman (2011 Nobel Prize in Medicine for discovery of dendritic cells) — long‑term scientific advisor to the parent organization.
Conditions Treated:
| Condition Group | Details |
|---|---|
| All Solid Tumors | HITV is applicable to any solid tumor type regardless of histology |
| Metastatic Cancer | Optimal for up to 5 lesions ≤3 cm; cases with 40+ lesions and tumors >10 cm have also been treated |
| Recurrent Cancer | For patients after standard treatments (surgery, chemotherapy, radiotherapy) |
| Stage IV Cancer | Including patients who have exhausted standard options |
| Prevention of Recurrence | preHITV for stage I–II patients after surgery |
Exclusion: Hematological cancers (leukemia, lymphoma with diffuse involvement) — HITV requires nodular tumor form.
Reported Clinical Outcomes:
- In a study of 26 advanced cancer patients: 13/26 achieved complete response (CR); 8/26 had local CR with recurrence elsewhere; 5/26 progressed. Median recurrence‑free survival: 377 days.
- In an expanded cohort (167 patients): among 37 patients with ≤5 lesions and ≤3 cm, 23 achieved CR; 5 had partial response (PR).
- Local control rate (no recurrence at treated site): ~90%.
International Center:
Yes, via facilitators. Direct appointments for international patients are possible, but coordination is handled through certified medical platforms: Medical Supporter (Fukuoka/Tokyo), Omotenashi Medical, Craig Trust, etc. Medical Supporter previously held official accreditation from Japan’s MFA as a medical visa guarantor (No. B‑066). Patients come from the USA, Australia, Taiwan, China, Russia, and other countries.
Languages:
Japanese (primary). English — via the international department and facilitators. Russian — via third‑party facilitators (Omotenashi Medical, Craig Trust, etc.).
Doctors / Leading Specialists:
| Name | Position | Experience |
|---|---|---|
| Dr. Kenichiro Hasumi | Founder, Chairman of HIRF and HASUMI Immuno Clinic | Graduated from Saitama Medical School (1978). Since 1988 — Chairman of Shukokai Inc. Visiting faculty at Thomas Jefferson University (USA) and Changchun University of Chinese Medicine (China). Honorary President of Jilin Cancer Center (China). Developer of HITV therapy. Long‑standing collaboration with Prof. Ralph Steinman (Nobel Prize 2011). Over 70 years of family history in cancer vaccines |
| Dr. Kohei Ueda | Current Director of HASUMI Immuno Clinic | Listed as active director on the Medical Supporter page |
| Dr. Yukimasa Aoki | Radiation Therapy Partner (IMRT/tomotherapy) | Chief Physician and Lecturer, Department of Radiology, The University of Tokyo Hospital. Trained at The Royal Marsden Hospital (UK). Special Appointee at the National Institute of Radiological Sciences, Japan. Technical Director, Emergency Radiation Medicine Division, Cabinet Office, Japan |
| Dr. Kiichiro Hasumi | Founder of Hasumi Vaccine (deceased) | Developed the vaccine in 1948. In 1961, conducted a clinical study in Nara Prefecture (Japan) on prevention of esophageal and gastric cancer in high‑risk groups. The vaccine has been used in over 20 countries |
Equipment — Confirmed:
| Equipment | Purpose |
|---|---|
| Cell Processing Center (CPC) | Culturing dendritic cells and T cells from patient blood; in‑house certified lab (rare for private clinics in Japan) |
| CT Scanner | Guidance for intratumoral dendritic cell injections |
| Apheresis System | Collection of mononuclear cells from patient blood for culturing |
| ELISPOT Assay | Evaluation of immune response (CTL activity) 3 months after treatment |
| Tomotherapy System (IMRT) | Intensity‑modulated radiation therapy delivered in combination with HITV (via partner radiology centers) |
Specific models of CT scanners and tomotherapy systems are not publicly listed.
Photographs:
Available on the Medical Supporter website (labeled “HASUMI Immuno Clinic image 1”). Video interviews with Dr. Hasumi are available on YouTube.
Official Websites:
- ICVS Tokyo Clinic: https://www.icv-s.org/
- Hasumi International Research Foundation: https://hasumifoundation.org/
- Hasumi, LLC (Shukokai International): https://hasumillc.net/
Contacts:
- ICVS Tokyo Clinic: +81 (0)3 3222 0551
- Shukokai Clinic: +81 3 3338 0710
- HASUMI Immuno Clinic (via Medical Supporter): +81‑92‑984‑3200
- HIRF (Washington): +1 202‑660‑0363
- Office Hours: 09:00–17:00; closed on Saturdays, Sundays, and public holidays
Accreditations & Partnerships:
- US patent granted December 13, 2011.
- Endowed chair at Thomas Jefferson University (USA): “K. Hasumi Professor of Medical Oncology,” established by Kenichiro Hasumi in honor of his father. The only known medical oncology chair in a US medical college established by a Japanese citizen.
- Research collaboration with the University of Maryland (USA).
- Partnership with Jilin Cancer Center (China) — Honorary President.
Key Differentiator:
The Hasumi Clinic is a narrowly specialized oncology‑immunology center with a 70‑year legacy, developing the proprietary HITV therapy (intratumoral dendritic cell injections combined with tomotherapy). The method is applicable to all solid tumors, reportedly has no serious side effects, and achieves ~90% local control. Limitations: not suitable for hematological cancers, requires nodular tumor form, and assumes adequate patient performance status. Typical timeframe to achieve remission is about one year. Direct appointments for foreign patients are possible but coordinated via third‑party medical facilitators.
The date of the last verification of the information: 06.10.2026.
Oncology
